ArticleBMC anesthesiology2026
Evaluation of clinically relevant sevoflurane concentrations in the development of malignant hyperthermia in an Ryr1 mutant mouse model.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMalignant hyperthermia (MH) is associated with mutations in the RYR1 gene; however, the effect of volatile anesthetic concentrations on the clinical symptoms of patients with MH is unknown. We investigated the effects of high concentrations of volatile anesthetics on MH development and progression.
methodsMH mouse models with R2509C mutation in Ryr1, all male, approximately 15 weeks old were administered 5%, 2.5% or 0.6% sevoflurane. The time at maximum temperature, maximum temperature, time at maximum heart rate, maximum heart rate, and time to asystole in the first experiment were measured. In the second experiment, blood samples were obtained from mice after the administration of 5% or 0.6% sevoflurane. In this experiment, the pH, base excess, and electrolyte and lactate levels were measured.
resultsAmong the 16 mutant mice used, all showed elevation of heart rate and body temperature and went into asystole. The 0.6% group showed longer time at maximum temperature than the 5% group (68.0 [67.0, 72.0] min vs 43.5 [18.3, 47.8] min, p = 0.046); while, maximum temperature was higher in the 0.6% group than the other groups (40.2 [38.2, 40.8] °C in the 5% group, 42.4 [42.2, 42.6] °C in the 2.5% group, and 44.7 [43.6, 45.3] °C in the 0.6% group); maximum heart rate was lower in the 5% group (480 [465, 503] bpm in the 5% group, 630 [570, 630] bpm in the 2.5% group, and 630 [630, 660] bpm in the 0.6% group). In the second experiment, the 5% group showed lower base excess (-23.4 [-24.4, -22.3] mmol/L vs -5.3 [-7.2, -4.3] mmol/L, p = 0.043) and higher lactate levels than the 0.6% group (20.00 [19.90, 20.00] mmol/L vs 4.80 [4.35, 7.88] mmol/L, p = 0.022). Potassium was relatively higher in the 5% group than in the 0.6% group.
conclusionsWhen exposed to high concentrations of sevoflurane, MH developed and progressed rapidly; however, the maximum temperature was lower than that in cases of low-concentration exposure, likely due to the rapid progression of electrolyte abnormalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.